文献速递妇科肿瘤

铂敏感复发性卵巢癌患者接受PARP抑制剂维持治疗期间CA-125与RECIST评估疾病进展的一致性差

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
PubMed 文献 · J Clin Oncol · 2024-01-12

该汇总分析纳入四项随机试验(Study 19、SOLO2、ARIEL3、NOVA)共1262例铂敏感复发性卵巢癌患者,评估CA-125与RECIST标准诊断疾病进展的一致性。CA-125进展阳性预测值为91%,但阴性预测值仅44%,安慰剂组更低至25%。作者认为近半数RECIST进展患者无CA-125进展,建议将定期CT纳入监测。

要点

  • CA-125进展对RECIST进展的阳性预测值为91%,阴性预测值仅44%。
  • 安慰剂组阴性预测值25%,显著低于PARP抑制剂组的53%。
  • RECIST-only进展患者中,64%的CA-125维持在正常范围内。

核心结论

  • 在铂敏感复发性卵巢癌接受PARP抑制剂维持治疗的患者中,近半数RECIST进展者无CA-125进展,对现行指南提出挑战。

研究设计与样本

  • 研究为四项随机试验(Study 19、SOLO2、ARIEL3、NOVA)的汇总分析,共纳入1262例参与者(PARP抑制剂组818例,安慰剂组444例)。

主要发现

  • 403例(32%)出现CA-125进展,其中366例RECIST进展一致,阳性预测值为91%(95%CI 88-93)。
  • 859例(68%)无CA-125进展者中,382例亦无RECIST进展,阴性预测值为44%(95%CI 41-48)。
  • PARP抑制剂组阳性预测值91%(95%CI 86-94),安慰剂组91%(95%CI 86-95);PARP抑制剂组阴性预测值53%(95%CI 49-57),安慰剂组25%(95%CI 20-31)。
  • 477例仅有RECIST进展者中,95%在维持治疗开始时CA-125正常,304例(64%)CA-125维持在正常范围内。
  • 仅有RECIST进展者中无腹膜病变的实体器官复发较CA-125与RECIST均进展者更常见(36% vs 24%;P<.001)。

关键数值与推荐

  • CA-125进展采用妇科肿瘤协作组(GCIG)标准定义,影像学进展采用RECIST v1.1标准。

临床怎么用

  • 作者建议将定期计算机断层扫描(CT)影像学检查作为监测的一部分,尤其适用于维持治疗开始时CA-125正常且正在治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cancer antigen-125 (CA-125) is recommended by treatment guidelines and widely used to diagnose ovarian cancer recurrence. The value of CA-125 as a surrogate for disease progression (PD) and its concordance with radiologic progression are unclear, particularly for women with platinum-sensitive relapsed ovarian cancer (PSROC) who have responded to chemotherapy and treated with maintenance poly(ADP-ribose) polymerase inhibitor (PARPi). METHODS: In this pooled analysis of four randomized trials of maintenance PARPi or placebo (Study 19, SOLO2, ARIEL3, and NOVA), we extracted data on CA-125 PD as defined by Gynecologic Cancer InterGroup criteria and RECIST v1.1. We evaluated the concordance between CA-125 and RECIST PD and reported on the negative predictive value (NPV) and positive predictive value (PPV). RESULTS: Of 1,262 participants (n = 818 PARPi, n = 444 placebo), 403 (32%) had CA-125 PD, and of these, 366 had concordant RECIST PD (PPV, 91% [95% CI, 88 to 93]). However, of 859 (68%) without CA-125 PD, 382 also did not have RECIST PD (NPV, 44% [95% CI, 41 to 48]). Within the treatment arms, PPV remained high (PARPi, 91% [95% CI, 86 to 94]; placebo, 91% [95% CI, 86 to 95]) but NPV was lower on placebo (PARPi, 53% [95% CI, 49 to 57]; placebo, 25% [95% CI, 20 to 31]). Of 477 with RECIST-only PD, most (95%) had a normal CA-125 at the start of maintenance therapy and the majority (n = 304, 64%) had CA-125 that remained within normal range. Solid organ recurrence without peritoneal disease was more common in those with RECIST-only PD than in those with CA-125 and RECIST PD (36% v 24%; P < .001). CONCLUSION: In patients with PSROC treated with maintenance PARPi, almost half with RECIST PD did not have CA-125 PD, challenging current guidelines. Periodic computed tomography imaging should be considered as part of surveillance, particularly in those with a normal CA-125 at the start of maintenance therapy and on treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tjokrowidjaja A, Friedlander ML, Ledermann JA, et al. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. J Clin Oncol. 2024. PMID: 38215359. doi:10.1200/JCO.23.01182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。